Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

20
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
20
Guidelines for Writing Outcome01:11

Guidelines for Writing Outcome

3.8K
When developing expected outcomes for a patient care plan, the nurse should adhere to the following recommendations:
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...
3.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Individual Variability of CD19+ B-Cell Repopulation in People With Multiple Sclerosis Treated With Extended Interval Dosing of Ocrelizumab.

European journal of neurology·2026
Same author

Mediation Analysis Between Brain Age, Disease-Modifying Factors, and Disability and Cognitive Performance in Multiple Sclerosis.

Neurology·2026
Same author

The impact of Information processing speed on visuospatial memory encoding and retrieval in multiple sclerosis.

Journal of clinical and experimental neuropsychology·2026
Same author

Breaking the PROMISE: poor association between brain volume loss and clinical disability worsening over 2 years of follow-up in primary progressive multiple sclerosis.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

Association of Brain Age With Physical Disability and Cognitive Impairment in People With Multiple Sclerosis of the Same Age.

Neurology·2025
Same author

The Effect of Use of Tricyclic Antidepressants or Serotonin-Norepinephrine Reuptake Inhibitors Versus Selective Serotonin Reuptake Inhibitors on the Risk of Urinary Tract Infection Among People With Multiple Sclerosis: A Nested Case-Control Study.

Pharmacoepidemiology and drug safety·2025

Related Experiment Video

Updated: May 3, 2026

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.9K

Clinical outcome measures in multiple sclerosis.

Bernard M J Uitdehaag1

  • 1Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands.

Handbook of Clinical Neurology
|February 11, 2014
PubMed
Summary

Accurate clinical outcome measures are vital for multiple sclerosis (MS) research and treatment. However, the commonly used Expanded Disability Status Scale (EDSS) has significant limitations, necessitating a search for better alternatives.

Keywords:
EDSSExpanded Disability Status ScaleGuy's Neurological Disability ScaleMS Functional CompositeMS Impact ScaleMSFCPatient reportedRelapse rateTimed 25-Foot Walkreliabilityvalidity

More Related Videos

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

10.6K
Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy
09:18

Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy

Published on: January 12, 2019

10.0K

Related Experiment Videos

Last Updated: May 3, 2026

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.9K
Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

10.6K
Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy
09:18

Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy

Published on: January 12, 2019

10.0K

Area of Science:

  • Neurology
  • Clinical Trials
  • Biostatistics

Background:

  • Clinical outcome measures are essential for understanding multiple sclerosis (MS) progression and treatment efficacy.
  • Current measures must be valid, reliable, responsive, and capture the multifaceted nature of MS.
  • Long-term disability-free survival is the primary treatment goal, but trial durations often necessitate extrapolation.

Purpose of the Study:

  • To evaluate the suitability of current clinical outcome measures in multiple sclerosis (MS) research.
  • To critically assess the Expanded Disability Status Scale (EDSS) as a primary outcome measure.
  • To highlight the challenge in finding a universally accepted, clinimetrically sound alternative outcome measure for MS.

Main Methods:

  • Review of existing literature on clinical outcome measures in multiple sclerosis.
  • Critical analysis of the clinimetric properties of the Expanded Disability Status Scale (EDSS).
  • Discussion on the requirements for ideal MS outcome measures.

Main Results:

  • The Expanded Disability Status Scale (EDSS) is widely used but possesses significant clinimetric weaknesses.
  • The long-term predictive value of many short-term response measures remains undetermined.
  • There is a critical need for outcome measures that are valid, reliable, responsive, and clinically relevant for MS.

Conclusions:

  • The Expanded Disability Status Scale (EDSS) has limitations that hinder its value as a sole outcome measure in multiple sclerosis.
  • Developing and validating new, comprehensive outcome measures for MS is a significant challenge.
  • The scientific community, clinicians, and regulatory agencies face the task of identifying superior alternatives for MS clinical trials.